Polydopamine-Mesoporous Silica Core-Shell Nanoparticles for Combined Photothermal Immunotherapy

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Immunology

Background:

• Cancer immunotherapy faces challenges in achieving potent and long-lasting antitumor responses.
• Responsive nanomaterials offer a platform for spatiotemporal control of immunological events.
• Existing immunotherapies can be limited by efficacy and systemic side effects.

Purpose of the Study:

• To develop a multifunctional, near-infrared (NIR)-responsive core-shell nanoparticle for cancer immunotherapy.
• To enable simultaneous photothermal ablation of cancer cells and triggered drug release.
• To investigate the synergistic effects of photothermal therapy and immunotherapy.

Main Methods:

• Fabrication of polydopamine nanoparticle core (photothermal agent) and mesoporous silica shell (drug carrier).
• Incorporation of a phase-change material as a gatekeeper for controlled release of tumor-associated antigens (TAA) and adjuvant (gardiquimod).
• In vivo evaluation in a mouse melanoma model to assess primary tumor regression and secondary tumor inhibition.

Main Results:

• The core-shell nanoparticles demonstrated NIR-triggered photothermal ablation of cancer cells.
• Concurrent release of TAA and adjuvant effectively activated antigen-presenting cells.
• Significant regression of primary tumors and inhibition of secondary tumors were observed in the mouse model.

Conclusions:

• Biocompatible and biodegradable NIR-responsive nanostructures can synergistically combine photothermal therapy and immunotherapy.
• This approach holds promise for generating potent and long-lasting antitumor immune responses.
• Responsive nanomaterials represent a promising platform for advanced cancer therapeutic strategies.